KR101317519B1 - Ｐｐａｒ 수용체 및 ｅｇｆ 수용체에 특이적인 화합물 및이들의 염, 및 의학 분야에서의 이들의 용도 - Google Patents

Ｐｐａｒ 수용체 및 ｅｇｆ 수용체에 특이적인 화합물 및이들의 염, 및 의학 분야에서의 이들의 용도 Download PDF

Info

Publication number
KR101317519B1
KR101317519B1 KR1020087003953A KR20087003953A KR101317519B1 KR 101317519 B1 KR101317519 B1 KR 101317519B1 KR 1020087003953 A KR1020087003953 A KR 1020087003953A KR 20087003953 A KR20087003953 A KR 20087003953A KR 101317519 B1 KR101317519 B1 KR 101317519B1
Authority
KR
South Korea
Prior art keywords
compound
cooh
group
formula
aminophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020087003953A
Other languages
English (en)
Korean (ko)
Other versions
KR20080039428A (ko
Inventor
지안카를로 나카리
세르지오 바로니
Original Assignee
지울리아니 인터내셔널 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37579831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101317519(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 지울리아니 인터내셔널 리미티드 filed Critical 지울리아니 인터내셔널 리미티드
Publication of KR20080039428A publication Critical patent/KR20080039428A/ko
Application granted granted Critical
Publication of KR101317519B1 publication Critical patent/KR101317519B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
KR1020087003953A 2005-07-22 2006-07-24 Ｐｐａｒ 수용체 및 ｅｇｆ 수용체에 특이적인 화합물 및이들의 염, 및 의학 분야에서의 이들의 용도 Active KR101317519B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000389A ITRM20050389A1 (it) 2005-07-22 2005-07-22 Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM2005A000389 2005-07-22
PCT/IE2006/000078 WO2007010516A2 (en) 2005-07-22 2006-07-24 Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field

Publications (2)

Publication Number Publication Date
KR20080039428A KR20080039428A (ko) 2008-05-07
KR101317519B1 true KR101317519B1 (ko) 2013-10-15

Family

ID=37579831

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087003953A Active KR101317519B1 (ko) 2005-07-22 2006-07-24 Ｐｐａｒ 수용체 및 ｅｇｆ 수용체에 특이적인 화합물 및이들의 염, 및 의학 분야에서의 이들의 용도

Country Status (23)

Country Link
US (6) US8153841B2 (https=)
EP (1) EP1910270B3 (https=)
JP (1) JP5312026B2 (https=)
KR (1) KR101317519B1 (https=)
CN (2) CN101243039B (https=)
AU (1) AU2006271165C1 (https=)
CA (1) CA2616146C (https=)
CY (1) CY1114294T1 (https=)
DK (1) DK1910270T6 (https=)
EA (2) EA014665B3 (https=)
ES (1) ES2421260T7 (https=)
HR (1) HRP20130549T4 (https=)
IL (2) IL188878A (https=)
IT (1) ITRM20050389A1 (https=)
MX (1) MX366596B (https=)
NO (1) NO340680B1 (https=)
NZ (2) NZ566045A (https=)
PL (1) PL1910270T6 (https=)
PT (1) PT1910270E (https=)
SI (1) SI1910270T1 (https=)
UA (1) UA100359C2 (https=)
WO (1) WO2007010516A2 (https=)
ZA (2) ZA200801671B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
IE20070129A1 (en) * 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
ITMI20072429A1 (it) 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
SI2805746T1 (sl) 2009-02-16 2020-10-30 Nogra Pharma Limited Alkilamido spojine in njihova uporaba
CN102906074A (zh) 2010-05-24 2013-01-30 东亚荣养株式会社 稠合咪唑衍生物
CA2864059C (en) * 2012-02-09 2020-04-28 Nogra Pharma Limited Methods of treating fibrosis
MX2014012652A (es) * 2012-04-18 2014-11-25 Nogra Pharma Ltd Metodo de tratamiento de la intolerancia a la lactosa.
FR2996545B1 (fr) 2012-10-08 2016-03-25 Ecole Polytech Procede microfluidique de traitement et d'analyse d'une solution contenant un materiel biologique, et circuit microfluidique correspondant.
US10257875B2 (en) * 2014-03-20 2019-04-09 Kyocera Corporation User terminal, communication control method, and base station
WO2017093444A1 (en) * 2015-12-01 2017-06-08 Nogra Pharma Limited Compositions for oral administration in the treatment of inflammatory bowel disease
EP3914227A1 (en) 2019-01-25 2021-12-01 Nogra Pharma Limited Compositions for use in preventing acne
EP4495101A3 (en) 2019-02-08 2025-04-30 Nogra Pharma Limited Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
TW202541791A (zh) 2023-12-20 2025-11-01 愛爾蘭商諾格拉製藥有限公司 痤瘡局部用調配物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0055689A1 (de) * 1980-12-22 1982-07-07 Schering Aktiengesellschaft In 3-Stellung substituierte 2,4,6-trihalogenierte Benzamide und deren Salze, deren Herstellung und Verwendung als Ersatzstoffe für natürliche Süssstoffe sowie Süssungsmittel auf Basis dieser Verbindungen
US4348223A (en) * 1980-12-05 1982-09-07 Ppg Industries, Inc. N-Alkyl-N-[3-(alkoxyalkyl)phenyl]-2-haloacetamide herbicides
EP0279096A2 (en) * 1987-02-05 1988-08-24 Kureha Kagaku Kogyo Kabushiki Kaisha Benzyl ether compound and process for producing the same

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB767788A (en) 1953-12-28 1957-02-06 Schering Corp Polyiodinated phenyl fatty acid compounds and process for their manufacture
US3211610A (en) * 1961-09-29 1965-10-12 Merck & Co Inc Benzoic acid ester derivatives for treating coccidiosis and method of using same
US3444232A (en) * 1966-05-18 1969-05-13 Squibb & Sons Inc O-alkyl or phenylalkyl benzohydroxamic acids
GB1359560A (en) 1972-02-25 1974-07-10 Merck & Co Inc Preparation of pyrrylsalicylic acid
US4036951A (en) * 1973-03-12 1977-07-19 Synergistics, Inc. Ultra-violet filtration with certain aminosalicylic acid esters
FR2440353A1 (fr) * 1978-11-03 1980-05-30 Science Union & Cie Nouveaux arylethanols, leurs procedes d'obtention et leur emploi comme medicament
JPS58194814A (ja) 1982-05-11 1983-11-12 Nippon Shinyaku Co Ltd 免疫調節作用を有する薬剤
IL69282A (en) 1982-09-02 1988-06-30 Euro Celtique Sa Method for the carboxylation of potassium phenoxide with carbon dioxide
AU1388388A (en) 1987-04-01 1988-10-06 Dak-Laboratoriet A/S Benzoic acid derivatives and use thereof
EP0352826B1 (en) 1988-05-05 1994-10-26 Tillotts Pharma Ag Use of 5-aminosalicylic acid in the treatment of dermatological disorders
US5519014A (en) * 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
DE69133348T3 (de) 1990-10-22 2011-05-12 Centre for Digestive Diseases Pty, Ltd. Behandlung von nicht-entzündlichen darmerkrankungen
US5262549A (en) * 1991-05-30 1993-11-16 Polaroid Corporation Benzpyrylium dyes, and processes for their preparation and use
US5302751A (en) 1992-01-21 1994-04-12 Ethyl Corporation Profen resolution
DE69331727D1 (de) 1992-06-30 2002-04-25 Howard K Shapiro Verwendung einer kombination bestehend aus einem aminderivat oder aminverwandten derivat der benzoesäure und einem amino-polysaccharide zur herstellung eines medikaments fuer die behandlung von entzündlichen erkrankungen
US5594151A (en) * 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
CA2190107A1 (en) 1994-05-11 1995-11-23 Secant Pharma, Llc Compositions for treatment of chronic inflammatory diseases
US5594015A (en) 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
WO1996030016A2 (en) 1995-03-28 1996-10-03 Janssen Pharmaceutica N.V. Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9617001D0 (en) 1996-08-13 1996-09-25 Tillotts Pharma Ag Oral composition
DE19647582A1 (de) * 1996-11-18 1998-05-20 Hoechst Ag Verfahren zur Herstellung von aromatischen Olefinen mittels Katalyse durch Palladaphosphacyclobutane
WO1998043081A1 (en) 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
US7098025B1 (en) * 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
AU9002798A (en) * 1997-09-19 1999-04-12 Ono Pharmaceutical Co. Ltd. Fused or nonfused benzene compounds
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6114382A (en) 1998-11-11 2000-09-05 Moretti; Itagiba G. Methods for treating inflammatory bowel disease
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
FR2791671B1 (fr) 1999-04-01 2001-05-11 Oreal Nouveaux composes derives d'esters d'acide benzoique, composition les comprenant et utilisation
GB9908647D0 (en) 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
US20040034067A1 (en) * 1999-04-15 2004-02-19 Macphee Colin Houston Novel method of treatment
GB9914371D0 (en) 1999-06-18 1999-08-18 Smithkline Beecham Plc Novel compounds
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
ATE275127T1 (de) 2000-04-19 2004-09-15 Neurotech Co Ltd Verbindungen, zusammensetzungen und verfahren zur vorbeugung der neurodegeneration bei akuten oder chronischen verletzungen des zentralen nervensystems
DE60135742D1 (de) * 2000-05-29 2008-10-23 Kyorin Seiyaku Kk Substituierte phenylpropionsäure-derivate
US7049342B2 (en) 2000-05-29 2006-05-23 Kyorin Pharmaceutical Co., Ltd. Substituted phenylpropionic acid derivatives
WO2002018324A2 (en) 2000-08-29 2002-03-07 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
AU2002222574A1 (en) 2000-12-05 2002-06-18 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
FR2822955B1 (fr) 2001-03-27 2003-10-03 Chru Lille Methode de diagnostic de maladies inflammatoires chroniques de l'intestin
WO2002085123A1 (en) 2001-04-18 2002-10-31 Merck & Co., Inc. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
CA2354921A1 (en) 2001-05-24 2002-11-24 Yasuo Konishi Drug evolution: drug design at hot spots
US20110105748A1 (en) * 2001-10-16 2011-05-05 Debnath Bhuniya Novel beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
US20030113815A1 (en) * 2001-12-19 2003-06-19 Pfizer Inc. Canine peroxisome proliferator activated receptor gamma
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20040115127A1 (en) * 2002-04-12 2004-06-17 Wright Samuel D. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
GB0303609D0 (en) 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
US20060159648A1 (en) 2003-02-17 2006-07-20 Davis Adrian F Novel therapeutic method and compositions for topical administration
US20060177444A1 (en) * 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
EP1654247B1 (en) 2003-07-21 2010-01-20 Merck Serono SA Alkynyl aryl carboxamides
GB2422782A (en) 2003-10-21 2006-08-09 Inspire Pharmaceuticals Inc Non-nucleotide compositions and method for treating pain
US20070093476A1 (en) * 2003-10-28 2007-04-26 Bhunia Debnath Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
JP2007513173A (ja) 2003-12-03 2007-05-24 スミスクライン・ビーチャム・コーポレイション ロシグリタゾンを用いる乾癬の治療
WO2005072113A2 (en) 2004-01-20 2005-08-11 Harty Richard F Compositions and methods of treatment for inflammatory diseases
WO2005084658A1 (en) 2004-03-04 2005-09-15 Arakis Ltd. Derivatives of actarit and their therapeutic use
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
US20060270635A1 (en) * 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
DE102005061472A1 (de) 2005-12-22 2007-07-05 Saltigo Gmbh Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-phenylpropionsäuren
WO2007096148A1 (en) 2006-02-23 2007-08-30 Lipid Nutrition B.V. Immunoregulation
US7645801B2 (en) 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
IE20070129A1 (en) 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
WO2009025854A1 (en) 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
ITMI20072429A1 (it) 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
US8030520B2 (en) 2008-03-31 2011-10-04 Saltigo Gmbh Process for preparing organic compounds by a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
SI2805746T1 (sl) 2009-02-16 2020-10-30 Nogra Pharma Limited Alkilamido spojine in njihova uporaba
EP2298321A1 (en) 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
EP2731605A4 (en) 2011-07-15 2015-02-25 Sla Pharma Ag Pharmaceutical compositions for rectal administration
WO2013064153A1 (en) 2011-10-31 2013-05-10 Claus Selch Larsen Prodrugs of non- steroid anti - inflammatory agents (nsaids)
CA2864059C (en) 2012-02-09 2020-04-28 Nogra Pharma Limited Methods of treating fibrosis
MX2014012652A (es) 2012-04-18 2014-11-25 Nogra Pharma Ltd Metodo de tratamiento de la intolerancia a la lactosa.
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
MX2014014657A (es) 2012-06-01 2015-08-10 Nogra Pharma Ltd Heterociclos bicíclicos capaces de modular las respuestas de los linfocitos t, y métodos de uso de los mismos.
KR20150053974A (ko) 2012-09-13 2015-05-19 노그라 파마 리미티드 모발 성장 억제 방법
EP2895160B1 (en) 2012-09-13 2018-05-30 Nogra Pharma Limited Methods of treating hair related conditions
WO2016154730A1 (en) 2015-04-02 2016-10-06 University Health Network Gut anti-inflammatory agents for regulation of high blood glucose levels
DK3307262T3 (da) 2015-06-15 2021-08-09 Nmd Pharma As Forbindelser til anvendelse ved behandling af neuromuskulære lidelser

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348223A (en) * 1980-12-05 1982-09-07 Ppg Industries, Inc. N-Alkyl-N-[3-(alkoxyalkyl)phenyl]-2-haloacetamide herbicides
EP0055689A1 (de) * 1980-12-22 1982-07-07 Schering Aktiengesellschaft In 3-Stellung substituierte 2,4,6-trihalogenierte Benzamide und deren Salze, deren Herstellung und Verwendung als Ersatzstoffe für natürliche Süssstoffe sowie Süssungsmittel auf Basis dieser Verbindungen
EP0279096A2 (en) * 1987-02-05 1988-08-24 Kureha Kagaku Kogyo Kabushiki Kaisha Benzyl ether compound and process for producing the same

Also Published As

Publication number Publication date
EA014665B1 (ru) 2010-12-30
HRP20130549T4 (hr) 2016-07-15
EP1910270B1 (en) 2013-05-08
US10016381B2 (en) 2018-07-10
ITRM20050389A1 (it) 2007-01-23
PL1910270T3 (pl) 2013-09-30
US9133099B2 (en) 2015-09-15
NO340680B1 (no) 2017-05-29
EA014665B3 (ru) 2016-09-30
JP5312026B2 (ja) 2013-10-09
BRPI0613396A8 (pt) 2017-12-26
HRP20130549T1 (en) 2013-07-31
US8710100B2 (en) 2014-04-29
NO20080325L (no) 2008-04-16
WO2007010516A3 (en) 2007-03-29
ZA201008268B (en) 2012-04-25
EA200800372A1 (ru) 2008-06-30
JP2009502777A (ja) 2009-01-29
AU2006271165A1 (en) 2007-01-25
DK1910270T6 (en) 2016-08-29
CN101243039A (zh) 2008-08-13
MX366596B (es) 2019-07-15
SI1910270T1 (sl) 2013-08-30
PT1910270E (pt) 2013-07-17
US20150045436A1 (en) 2015-02-12
US20150265563A1 (en) 2015-09-24
EA017566B1 (ru) 2013-01-30
CA2616146A1 (en) 2007-01-25
UA100359C2 (uk) 2012-12-25
US20170312239A1 (en) 2017-11-02
DK1910270T3 (da) 2013-07-01
EP1910270B3 (en) 2016-05-11
CN102020577B (zh) 2013-03-13
US9345680B2 (en) 2016-05-24
CA2616146C (en) 2015-06-30
KR20080039428A (ko) 2008-05-07
IL188878A (en) 2013-04-30
IL205992A (en) 2014-05-28
CN102020577A (zh) 2011-04-20
AU2006271165C1 (en) 2016-11-17
WO2007010516A2 (en) 2007-01-25
PL1910270T6 (pl) 2017-05-31
US8153841B2 (en) 2012-04-10
EP1910270A2 (en) 2008-04-16
EA201000708A1 (ru) 2010-10-29
ES2421260T3 (es) 2013-08-30
ES2421260T7 (es) 2016-10-11
ZA200801671B (en) 2011-02-23
NZ566045A (en) 2012-04-27
CY1114294T1 (el) 2016-08-31
AU2006271165B2 (en) 2012-01-19
NZ592228A (en) 2012-10-26
US20090048343A1 (en) 2009-02-19
US20130005813A1 (en) 2013-01-03
BRPI0613396A2 (pt) 2011-01-11
US9561202B2 (en) 2017-02-07
US20150265562A1 (en) 2015-09-24
CN101243039B (zh) 2013-04-03
IL188878A0 (en) 2008-04-13

Similar Documents

Publication Publication Date Title
US10016381B2 (en) Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
US8450506B2 (en) Compounds and their salts specific to the PPAR receptors and the EGF Receptors and their use in the medical field
BRPI0613396B1 (pt) Composto, uso do mesmo, e, composição farmacêutica

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080219

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110318

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20121030

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20130402

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20130820

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20131004

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20131004

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
J202 Request for trial for correction [limitation]
PJ0202 Trial for correction

Comment text: Request for Trial

Patent event date: 20160401

Patent event code: PJ02022R01D

Comment text: Registration of Establishment

Patent event date: 20131004

Patent event code: PJ02021E01I

Appeal kind category: Correction

Decision date: 20170320

Request date: 20160401

Appeal identifier: 2016105000038

FPAY Annual fee payment

Payment date: 20160923

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20160923

Start annual number: 4

End annual number: 4

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20170320

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2016105000038

Request date: 20160401

Appeal kind category: Correction

Decision date: 20170320

FPAY Annual fee payment

Payment date: 20171011

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20171011

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20180921

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20180921

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20191021

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20191021

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20201006

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20201006

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20211020

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20211020

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20220922

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20220922

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20230921

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee